Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Single Blind, Randomized Crossover Study to Evaluate the Safety and Efficacy of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

NCT04999046 is registered in ClinicalTrials.gov with NaviFUS Corporation as lead sponsor.

NCT NCT04999046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04999046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Single Blind, Randomized Crossover Study to Evaluate the Safety and Efficacy of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
Lead sponsor
NaviFUS Corporation
Phase
Not applicable
Overall status
Completed
Start date
October 7, 2021
Completion date
July 31, 2024
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug resistant epilepsy, epilepsy, seizure, seizure disorder